Progress in the pursuit of therapeutic adenosine receptor antagonists.
Ever since the discovery of the hypotensive and bradycardiac effects of adenosine, adenosine receptors continue to represent promising drug targets. First, this is due to the fact that the receptors are expressed in a large variety of tissues. In particular, the actions of adenosine (or methylxanthine antagonists) in the central nervous system, in the circulation, on immune cells, and on other tissues can be beneficial in certain disorders. Second, there exists a large number of ligands, which have been generated by introducing several modifications in the structure of the lead compounds (adenosine and methylxanthine), some of them highly specific. Four adenosine receptor subtypes (A1, A2A, A2B, and A3) have been cloned and pharmacologically characterized, all of which are G protein-coupled receptors. Adenosine receptors can be distinguished according to their preferred mechanism of signal transduction: A1 and A3 receptors interact with pertussis toxin-sensitive G proteins of the Gi and Go family; the canonical signaling mechanism of the A2A and of the A2B receptors is stimulation of adenylyl cyclase via Gs proteins. In addition to the coupling to adenylyl cyclase, all four subtypes may positively couple to phospholipase C via different G protein subunits. The development of new ligands, in particular, potent and selective antagonists, for all subtypes of adenosine receptors has so far been directed by traditional medicinal chemistry. The availability of genetic information promises to facilitate understanding of the drug-receptor interaction leading to the rational design of a potentially therapeutically important class of drugs. Moreover, molecular modeling may further rationalize observed interactions between the receptors and their ligands. In this review, we will summarize the most relevant progress in developing new therapeutic adenosine receptor antagonists.
Moro
Stefano
S
Molecular Modeling Section, Dipartimento di Scienze Farmaceutiche, Università di Padova, Via Marzolo 5, I-35131 Padova, Italy. stefano.moro@unipd.it
Gao
Zhan-Guo
ZG
Jacobson
Kenneth A
KA
Spalluto
Giampiero
G
D058916:Adenosine A1 Receptor Antagonists; D058917:Adenosine A2 Receptor Antagonists; D058918:Adenosine A3 Receptor Antagonists; D000595:Amino Acid Sequence; D000818:Animals; D005419:Flavonoids / Q000627:therapeutic use; D006571:Heterocyclic Compounds / Q000627:therapeutic use; D006801:Humans; D058915:Purinergic P1 Receptor Antagonists; D021281:Quantitative Structure-Activity Relationship; D011799:Quinazolines / Q000627:therapeutic use; D043704:Receptor, Adenosine A2B; D014230:Triazoles / Q000627:therapeutic use; D014970:Xanthines / Q000627:therapeutic use
D058916:Adenosine A1 Receptor Antagonists; D058917:Adenosine A2 Receptor Antagonists; D058918:Adenosine A3 Receptor Antagonists; D005419:Flavonoids; D006571:Heterocyclic Compounds; D058915:Purinergic P1 Receptor Antagonists; D011799:Quinazolines; D043704:Receptor, Adenosine A2B; D014230:Triazoles; D014970:Xanthines; C051360:1,3-dipropyl-8-cyclopentylxanthine